Pancreas release from

Insulin released from the pancreas is monomeric and acts... 

Improvement of glucose utihzation (Leklem., 1998). Non-starchy polysaccharide Improving the immune function and increased insulin release from the pancreas (Masayoshi et a/.,1987). 

The pancreatic juice is released through the ampulla of Vater into the duodenum to aid in the digestive process as well as buffer acidic fluid released from the stomach (Fig. 20-1). The pancreas contains a trypsin inhibitor to prevent autolysis. 

A reduction in insulin release from the pancreas may be caused by which of the following diuretics ... 

To prevent self-digestion, the pancreas releases most proteolytic enzymes into the duodenum in an inactive form as proenzymes (zymogens). Additional protection from the effects of premature activation of pancreatic proteinases is provided by proteinase inhibitors in the pancreatic tissue, which inactivate active enzymes by complex formation (right). 

Metabolic Effects. The hyperglycemic effect of nickel is discussed under endocrine effects because it appears to be secondary to the effects on catecholamine release from the adrenal gland and central nervous system and to the effects on insulin release by the pancreas. 

The regulation of calcitonin synthesis and release from the parafollicular C cells of the thyroid gland is calcium dependent. Rising serum calcium is the principal stimulus responsible for calcitonin synthesis and release. Other hormones, such as glucagon, gastrin, and serotonin, also stimulate calcitonin release. Calcitonin has been isolated in tissues other than the parafollicular C cells (parathyroid, pancreas, thymus, adrenal), but it is not known whether this material is biologically active. 

Diazoxide inhibits insulin release from the pancreas (probably by opening potassium channels in the beta cell membrane) and is used to treat hypoglycemia secondary to insulinoma. Occasionally, hyperglycemia complicates diazoxide use, particularly in persons with renal insufficiency. 

The major action of sulfonylureas is to increase insulin release from the pancreas (Table 41-5). Two additional mechanisms of action have been proposed—a reduction of serum glucagon levels and closure of potassium channels in extra pancreatic tissue (which are of unknown but probably minimal significance). 

Physiological - happening at different sites and counteracting each other. Diazoxide, used for hypertension, blocks insulin release from the pancreas and so has a hyperglycemic effect. Insulin, on the other hand, lowers blood glucose and is hypoglycemic. 

In the duodenum, dietary lipids are degraded by pancreatic enzymes triacylglycerol by pancreatic lipase, phospholipids by phospholipase A2 and lysophospholipase, and cholesteryl esters by cholesterol esterase. Enzyme release from the pancreas is controlled by cholecystokinin, produced by cells in the intestinal mucosa. 

Nickel also may act to stimulate or inhibit the release of various hormones (Nielsen, 1971. 1972 Dormer et al., 1973 Clay, 1975 Harak-Sunderman, 1975). Nickel has been found to inhibit insulin release from the pancreas (Dormer et al.. 1973 Clay, 1975). and stimulates glucagon secretion (Horak-S underman, 1975). 

An important interaction between insulin and glucagon may also take place directly within the pancreas, and insulin appears to be the dominant hormone controlling this interaction.29,53 When the beta cells sense an increase in blood glucose, they release insulin, which in turn inhibits glucagon release from the alpha... 

The major action of sulfonylureas is to increase insulin release from the pancreas (Table 41-5). 

---